Axsome stocktwits.

Axsome Therapeutics has a twelve month low of $19.38 and a twelve month high of $74.10. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -6.98 and a beta of 2.49. The company has a current ratio of 3.54, a quick ratio of 3.54 and a debt-to-equity ratio of 3.36. About Axsome TherapeuticsAxsome reported its Q1'23 earnings yesterday - net loss was $(0.26) per share. The company's 2 commercial products - newly approved Auvelity and Sunosi, acquired from Jazz Pharmaceuticals earned $29m. Axsome is a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders. AXSM Price Action: Axsome has a 52-week high of $71.98 and a 52-week low of $20.63. The stock was up 17.1% at $66.55 at time of publication, according to Benzinga Pro. 1 Reply.Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 3.7% americanbankingnews.com - October 1 at 4:12 AM: AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm businesswire.com - September 28 at 11:00 PMShares of Axsome Therapeutics ( AXSM 1.09%) were soaring 12.7% higher as of 11:19 a.m. ET on Thursday. The company didn't report any new developments, so what's behind the nice gain? There are two ...

about axsome We are committed to developing products that meaningfully improve the lives of patients. Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS‑14. learn about our pipeline Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.Get all financial information for Axsome Therapeutics Inc (AXSM) including Market Capitalization, PE Ratio, EBITDA, EPS, previous close and open price, 52 week high & 52 week low, Beta and much more.about axsome We are committed to developing products that meaningfully improve the lives of patients. Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS‑14. learn about our pipeline Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.

Get all financial information for Axsome Therapeutics Inc (AXSM) including Market Capitalization, PE Ratio, EBITDA, EPS, previous close and open price, 52 week high & 52 week low, Beta and much more

Shares of Axsome Therapeutics ( AXSM 1.09%) were soaring 12.7% higher as of 11:19 a.m. ET on Thursday. The company didn't report any new developments, so what's behind the nice gain? There are two ...11 analysts have issued 1 year price objectives for Axsome Therapeutics' stock. Their AXSM share price forecasts range from $81.00 to $180.00. On average, they expect the company's share price to reach $102.40 in the next year. This suggests a possible upside of 54.0% from the stock's current price.Find real-time AXSM - Axsome Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.Vanguard Group currently owns 3,111,500 shares of AXSM worth $138,835,000. Norges Bank also entered the scene as a new investor during the fourth quarter and purchased a stake in Axsome Therapeutics with an approximate value of $19,776,000. With these investments from various hedge funds and institutional investors combined, it can be estimated ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

finance.yahoo.com - October 2 at 10:10 AM. Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 3.7%. americanbankingnews.com - October 1 at 4:12 AM. AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm.

Sync with Stocktwits. Latest AXSOME THERAPEUTICS (AXSM) stock news, Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the develo...First Quarter 2023 Financial Highlights. Total revenue for the first quarter of 2023 was $94.6 million, consisting of net product sales of $28.6 million, license revenue of $65.7 million, and ...stocktwits. Disclaimer & Important Information. StockEarnings.com is owned and published by StockEarnings, Inc ("SE"). Their results are not typical and your ...Axsome Therapeutics, Inc. (. AXSM Quick Quote. AXSM - Free Report) incurred an adjusted loss of $1.28 per share in the fourth quarter of 2022, wider than the Zacks Consensus Estimate of a loss of ...Overall, Axsome Therapeutics looks poised to earn at least a few approvals in the next two years and grow its revenue long after that. That's why the biotech still looks like a buy right now ...It was developed by Jazz Pharmaceuticals and approved in mid-2019 before being acquired by Axsome for $53 million (plus royalties) on 5/9/22. Sunosi grew revenue 105% in 2021 to $58 million and ...Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock. Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the closing of its ...

83.56 +0.65(+0.78%) Gold 1,886.00 +3.00(+0.16%) Advertisement Axsome Therapeutics, Inc. (AXSM) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 66.51 -3.68 (-5.24%) At close:... 83.56 +0.65(+0.78%) Gold 1,886.00 +3.00(+0.16%) Advertisement Axsome Therapeutics, Inc. (AXSM) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 66.51 -3.68 (-5.24%) At close:... Axsome Therapeutics Inc 52 week high is $91.29 as of October 12, 2023. What is the 52-week low for Axsome Therapeutics Inc? 52 week low is the lowest price of a stock in the past 52 weeks, or one year.Best-in-Class Portfolio Monitoring. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts.Zacks Equity Research March 29, 2023. Better trading starts here. A month has gone by since the last earnings report for Axsome Therapeutics ( AXSM - Free Report) . Shares have lost about 9.8% in ...axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city. Facebook Twitter Stocktwits Discord Patreon. Explore About Us Gold ...

Get all financial information for Axsome Therapeutics Inc (AXSM) including Market Capitalization, PE Ratio, EBITDA, EPS, previous close and open price, 52 week high & 52 week low, Beta and much moreGet the latest price and volume on Axsome Therapeutics in IBD stock charts. Our investment research resources are provided to help you make informed investment decisions.

Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available. See More. AXSM Related stocks. Symbol 3M %Chg ; AXSM -7.18% : Axsome Thera: AMGN +19.95% : Amgen Inc: BMYAxsome Therapeutics Inc. Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications.Mexico - Mexico Delayed Price. Currency in MXN. Follow. 1,247.00 0.00 (0.00%) At close: 09:42AM CST. Find the latest Axsome Therapeutics, Inc. (AXSM.MX) stock discussion in Yahoo Finance's forum ...86.03 -0.35(-0.41%) Gold 1,876.30 +12.00(+0.64%) Advertisement Axsome Therapeutics, Inc. (AXSM) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 70.38 +1.78 (+2.59%) At...Axsome expects that its operating expenses will increase year over year as the Company commercializes Sunosi and Auvelity and continues to advance its pipeline. Commercial Highlights. Auvelity. Axsome commercially launched Auvelity on October 19, 2022. Early prescription trends reflect strong adoption from prescribers and patients.Axsome Therapeutics opened for trading on Wednesday at $28.78, closer to its 52-week low of $19.38 than to its 52-week high of $78. The Case For Global Blood Therapeutics: This South San Francisco ...Axsome Therapeutics ( AXSM) expects its eight products to generate up to $11.5 billion in peak U.S. sales, the company said in a filing that sent AXSM stock zooming higher Wednesday. This is the ...Jazz will receive from Axsome a total upfront payment of $53 million, a high single-digit royalty on Axsome’s U.S. net sales of Sunosi in the current indication, and a mid single-digit royalty ...According to 10 analyst offering 12-month price targets in the last 3 months, Axsome Therapeutics has an average price target of $118.4 with a high of $210.00 and a low of $52.00.

Axsome Therapeutics saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 8,120,000 shares, a drop of 1.5% from the previous total of 8,240,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting ...

We are committed to developing products that meaningfully improve the lives of patients. Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS‑14. learn about our pipeline. Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Find the latest Axsome Therapeutics, Inc. (AXSM) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other ...Axsome Therapeutics Options Chain & Prices (NASDAQ:AXSM) S&P 500 4,337.44. DOW 34,006.88. QQQ 359.61. 2 Must-Have Silicon Companies That Don't Make Microchips.Get the latest Axsome Therapeutics, Inc. (AXSM) stock news and headlines to help you in your trading and investing decisions.Axsome is a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders. AXSM Price Action: Axsome has a 52-week high of $71.98 and a 52-week low of $20.63. The stock was up 17.1% at $66.55 at time of publication, according to Benzinga Pro. 1 Reply. We are committed to developing products that meaningfully improve the lives of patients. Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS‑14. learn about our pipeline. Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.VDOMDHTMLtml>. Axsome Therapeutics Inc (AXSM) Stock Price Today, News, Quotes, FAQs and Fundamentals. AXSM Stock Price - Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies …The shares of Axsome Therapeutics (NASDAQ:AXSM) have dropped ~26% in the pre-market Monday after the clinical-stage pharmaceutical company announced that the U.S. Food and Drug Administration (FDA ...11 oct. 2022 ... Chen Reveals His Picks for Last Quarter. SilverBiotechnology / Pharmaceuticals. Share on Stocktwits ... Axsome Therapeutics Inc. (AXSM:NASDAQ), a ...Links AXSM StockTwits. Show Market Indexes. Detailed Chart. Chart Settings. Overall. 80%. Bullish. 0%. Trade Quality. Long. 40%. Short. Breakout Long Short. Tap ...

Axsome Therapeutics. 08/11/23 Mizuho. Axsome Therapeutics price target raised to $100 from $95 at Mizuho. 08/08/23 H.C. Wainwright. Axsome Therapeutics price target lowered to $180 from $190 at H.C. Wainwright. 08/08/23 BofA. Axsome Therapeutics upgraded to Neutral from Underperform at BofA. 08/08/23 Piper Sandler.Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16 th Floor New York, NY 10007 Tel: 212-332-3243 Email: [email protected] the latest price and volume on Axsome Therapeutics in IBD stock charts. Our investment research resources are provided to help you make informed investment decisions.Axsome stock has a high Relative Strength Rating of 97, putting shares in the top 3% of all stocks in terms of 12-month performance, according to IBD Digital. Follow Allison Gatlin on Twitter at ...Instagram:https://instagram. dig to china cool mathcheck att.net emailctsy fuse meaningjamaal williams or ezekiel elliott Axsome reported its Q1'23 earnings yesterday - net loss was $(0.26) per share. The company's 2 commercial products - newly approved Auvelity and Sunosi, acquired from Jazz Pharmaceuticals earned $29m. George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Axsome Therapeutics, Bristol Myers Squibb, and Tesla. The Motley Fool recommends DexCom ... 2013 chrysler town and country oil capacityfpl outage map port st lucie Axsome Therapeutics, Inc. NDA resubmission of AXS-07 for treatment of patients with migraine expected 2nd half 2023 after FDA meeting determined that CMC issues are the only things that need to be ... hyvee prairie trail pharmacy Axsome Therapeutics, Inc. Fed, Rising Energy Costs Pressure Stocks The Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and regularly updated by Argus ...07/17/23 11:57 AM Post #640 Re: #639: @georgejjl - New mid term topic $100.00 by or before Per Fidelity: BY Benzinga — 6:18 AM ET 07/17/2023 HC Wainwright & Co. analyst Raghuram Selvaraju maintains...